Company News: NEO New Oncology AG launches liquid biopsy test “NEOliquid” for comprehensive cancer diagnostics from a single blood sample

NEO New Oncology AG announced today the commercial launch of “NEOliquid”, a non-invasive cancer diagnostics test. NEOliquid is uniquely able to detect all therapeutically relevant point mutations, small insertions and deletions, translocations and copy number changes from a single blood sample, offering a painless and low-risk alternative to a tissue biopsy. NEOliquid comprises 39 genes relevant for the treatment of solid tumors, offering the physician with a rational decision making guide to match their patient with the best targeted treatment. NEO New Oncology AG is the only European provider performing comprehensive routine molecular cancer diagnostics in both clinical tissue samples and blood.

NEOliquid identifies clinically relevant, cancer-specific point mutations, insertions, deletions and gene fusions in circulating cell-free DNA down to an allele frequency of 0.1%. In addition, NEOliquid is able to detect copy number alterations in tiny amounts of circulating tumor DNA.

NEOliquid enables indirect analysis of both the primary tumor as well as its metastases, capturing the entire heterogeneity of the disease. The test can be applied to reveal additional possible therapeutic options for the patient, e.g. in the case of relapse or if the patient’s tumor has become resistant to targeted therapy. NEOliquid is suited for therapy control and therapy decisions for cancer patients experiencing recurrence of cancer, avoiding risk-prone and painful re-biopsies. NEOliquid is applicable to patients with solid tumors, such as lung, skin, breast, stomach, intestinal or ovarian cancer, or in childhood malignancies such as neuroblastoma. As little as 18 milliliters of blood are required for NEOliquid analysis. Samples can be shipped at room temperature via standard mail or courier service.